Distributor inventory | Tablet

Type 2 diabetes mellitus (as add-on to diet and exercise) to control post-meal (postprandial) blood sugar; used when single therapy is insufficient.

Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and glucose absorption in the intestine, reducing post-meal glucose spikes. Repaglinide is a meglitinide that stimulates pancreatic insulin release by closing ATP-sensitive potassium channels in beta cells, mainly lowering postprandial glucose.

Oral tablet. Take as prescribed, typically just before meals (0–30 minutes before); if you skip a meal, skip the dose to reduce hypoglycaemia risk. Follow diet/exercise plan; monitor blood glucose regularly.

Hypoglycaemia, abdominal pain, flatulence, diarrhoea, nausea, headache, dizziness, weight gain

Risk of hypoglycaemia (higher if meals are delayed/skipped, with alcohol, or with other antidiabetics); carry glucose/sugar for low sugar episodes. Use with caution in liver impairment; monitor liver function if advised. Voglibose may cause significant gas/diarrhoea; avoid in inflammatory bowel disease, intestinal obstruction, or chronic intestinal disorders. Use caution in renal impairment, elderly, and malnourished patients. Not a substitute for insulin; seek medical advice during fever, infection, surgery, or trauma.

Gemfibrozil (contraindicated/avoid with repaglinide—marked hypoglycaemia risk), Clopidogrel (avoid/major interaction—raises repaglinide levels), Azole antifungals (e.g., itraconazole/ketoconazole), Macrolides (e.g., clarithromycin), Rifampicin (may reduce effect), Cyclosporine, Beta-blockers (may mask hypoglycaemia), Other antidiabetic medicines/insulin (additive hypoglycaemia), Alcohol (increases hypoglycaemia risk)

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep in original blister pack and out of reach of children.

Repaglinide 1 mg + Voglibose 0.3 mg tablets (generic), Volix R 0.3/0.5 Tablet, Volix R 0.2/1 Tablet, Prandial VG 0.3/1 Tablet, Repag V 0.3/1 Tablet